ReviewCureus2026
Histological and Immunohistochemical Biomarkers for Wound Age Estimation in Human Skin: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shengji ointment accelerates diabetic foot ulcer wound healing by regulating inflammatory microenvironment.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate estimation of wound age is a critical challenge in forensic pathology, particularly for determining wound vitality and the interval between injury and death. Conventional histology often lacks sensitivity in the early post-traumatic stages, prompting investigation into molecular and immunohistochemical biomarkers. This review synthesizes evidence on histological and immunohistochemical markers used for wound age estimation in human skin, with attention to their applicability across different post-traumatic intervals. Very early wounds, from minutes up to one hour, are best characterized by markers related to haemostasis, mast cell activation, and early cytokine release, including fibronectin, CD62p (P-selectin), factor VIII-related antigen, tumor necrosis factor-alpha (TNF-α), and tryptase. Early wound stages, spanning hours, show transient mast cell accumulation and cytokine expression preceding inflammatory cell infiltration. Intermediate wounds, from one to ten days, are associated with immune cell phenotyping and chemokine expression, such as CD14, CD68, interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1 alpha (MIP-1α). Late wounds, seven days or more, are marked by indicators of hypoxia response, angiogenesis, cellular stress, and extracellular matrix remodeling, including oxygen-regulated protein 150 (ORP150), ubiquitin, vascular endothelial growth factor (VEGF), matrix metalloproteinases, collagens, and aquaporins. No single marker provides sufficient accuracy across all healing phases, highlighting the need for multimodal approaches that combine morphological assessment with panels of temporally complementary biomarkers. Standardization of methods and additional high-quality human studies are essential to improve the reliability and forensic applicability of wound age estimation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.